CLARITIN-D 12 HOUR OTC
Generic Name and Formulations:
Loratadine 5mg, pseudoephedrine sulfate 120mg; ext-rel tabs.
Merck & Co., Inc.
Indications for CLARITIN-D 12 HOUR:
Seasonal allergic rhinitis with nasal congestion.
Swallow whole. 1 tab every 12 hrs. Renal insufficiency (CrCl <30mL/min): 1 tab once daily.
Narrow-angle glaucoma. Urinary retention. Severe hypertension or coronary artery disease. During or within 14 days of MAOIs.
Hepatic or renal impairment. Hypertension. Ischemic heart disease. Increased intraocular pressure. Thyroid disease. GI or urinary obstruction. Seizures. Diabetes. Pregnancy. Nursing mothers: not recommended.
Antihistamine + sympathomimetic.
See Contraindications. Pseudoephedrine: Antagonizes antihypertensives. Increased ectopic pacemaker activity with digitalis.
Dry mouth, insomnia, somnolence, nervousness, dizziness, dyspepsia, pharyngitis, anorexia, bronchospasm.
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- Handling Chemotherapy Premedications
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|